256 related articles for article (PubMed ID: 24770886)
1. Targeting the MUC1-C oncoprotein inhibits self-renewal capacity of breast cancer cells.
Alam M; Rajabi H; Ahmad R; Jin C; Kufe D
Oncotarget; 2014 May; 5(9):2622-34. PubMed ID: 24770886
[TBL] [Abstract][Full Text] [Related]
2. Targeting the MUC1-C oncoprotein downregulates HER2 activation and abrogates trastuzumab resistance in breast cancer cells.
Raina D; Uchida Y; Kharbanda A; Rajabi H; Panchamoorthy G; Jin C; Kharbanda S; Scaltriti M; Baselga J; Kufe D
Oncogene; 2014 Jun; 33(26):3422-31. PubMed ID: 23912457
[TBL] [Abstract][Full Text] [Related]
3. Mucin 1 is a potential therapeutic target in cutaneous T-cell lymphoma.
Jain S; Stroopinsky D; Yin L; Rosenblatt J; Alam M; Bhargava P; Clark RA; Kupper TS; Palmer K; Coll MD; Rajabi H; Pyzer A; Bar-Natan M; Luptakova K; Arnason J; Joyce R; Kufe D; Avigan D
Blood; 2015 Jul; 126(3):354-62. PubMed ID: 26048911
[TBL] [Abstract][Full Text] [Related]
4. Dependence on the MUC1-C oncoprotein in non-small cell lung cancer cells.
Raina D; Kosugi M; Ahmad R; Panchamoorthy G; Rajabi H; Alam M; Shimamura T; Shapiro GI; Supko J; Kharbanda S; Kufe D
Mol Cancer Ther; 2011 May; 10(5):806-16. PubMed ID: 21421804
[TBL] [Abstract][Full Text] [Related]
5. MUC1-C confers EMT and KRAS independence in mutant KRAS lung cancer cells.
Kharbanda A; Rajabi H; Jin C; Alam M; Wong KK; Kufe D
Oncotarget; 2014 Oct; 5(19):8893-905. PubMed ID: 25245423
[TBL] [Abstract][Full Text] [Related]
6. Oncogenic MUC1-C promotes tamoxifen resistance in human breast cancer.
Kharbanda A; Rajabi H; Jin C; Raina D; Kufe D
Mol Cancer Res; 2013 Jul; 11(7):714-23. PubMed ID: 23538857
[TBL] [Abstract][Full Text] [Related]
7. Direct targeting of the mucin 1 oncoprotein blocks survival and tumorigenicity of human breast carcinoma cells.
Raina D; Ahmad R; Joshi MD; Yin L; Wu Z; Kawano T; Vasir B; Avigan D; Kharbanda S; Kufe D
Cancer Res; 2009 Jun; 69(12):5133-41. PubMed ID: 19491255
[TBL] [Abstract][Full Text] [Related]
8. Targeting MUC1-C inhibits the AKT-S6K1-elF4A pathway regulating TIGAR translation in colorectal cancer.
Ahmad R; Alam M; Hasegawa M; Uchida Y; Al-Obaid O; Kharbanda S; Kufe D
Mol Cancer; 2017 Feb; 16(1):33. PubMed ID: 28153010
[TBL] [Abstract][Full Text] [Related]
9. MUC1-C activates the TAK1 inflammatory pathway in colon cancer.
Takahashi H; Jin C; Rajabi H; Pitroda S; Alam M; Ahmad R; Raina D; Hasegawa M; Suzuki Y; Tagde A; Bronson RT; Weichselbaum R; Kufe D
Oncogene; 2015 Oct; 34(40):5187-97. PubMed ID: 25659581
[TBL] [Abstract][Full Text] [Related]
10. MUC1-C activates BMI1 in human cancer cells.
Hiraki M; Maeda T; Bouillez A; Alam M; Tagde A; Hinohara K; Suzuki Y; Markert T; Miyo M; Komura K; Ahmad R; Rajabi H; Kufe D
Oncogene; 2017 May; 36(20):2791-2801. PubMed ID: 27893710
[TBL] [Abstract][Full Text] [Related]
11. Dipyridamole prevents triple-negative breast-cancer progression.
Spano D; Marshall JC; Marino N; De Martino D; Romano A; Scoppettuolo MN; Bello AM; Di Dato V; Navas L; De Vita G; Medaglia C; Steeg PS; Zollo M
Clin Exp Metastasis; 2013 Jan; 30(1):47-68. PubMed ID: 22760522
[TBL] [Abstract][Full Text] [Related]
12. Cooperative interaction between the MUC1-C oncoprotein and the Rab31 GTPase in estrogen receptor-positive breast cancer cells.
Jin C; Rajabi H; Pitroda S; Li A; Kharbanda A; Weichselbaum R; Kufe D
PLoS One; 2012; 7(7):e39432. PubMed ID: 22792175
[TBL] [Abstract][Full Text] [Related]
13. MUC1 is a potential target for the treatment of acute myeloid leukemia stem cells.
Stroopinsky D; Rosenblatt J; Ito K; Mills H; Yin L; Rajabi H; Vasir B; Kufe T; Luptakova K; Arnason J; Nardella C; Levine JD; Joyce RM; Galinsky I; Reiter Y; Stone RM; Pandolfi PP; Kufe D; Avigan D
Cancer Res; 2013 Sep; 73(17):5569-79. PubMed ID: 23867470
[TBL] [Abstract][Full Text] [Related]
14. miR-200c suppresses stemness and increases cellular sensitivity to trastuzumab in HER2+ breast cancer.
Tang H; Song C; Ye F; Gao G; Ou X; Zhang L; Xie X; Xie X
J Cell Mol Med; 2019 Dec; 23(12):8114-8127. PubMed ID: 31599500
[TBL] [Abstract][Full Text] [Related]
15. MUC1-C oncoprotein confers androgen-independent growth of human prostate cancer cells.
Rajabi H; Ahmad R; Jin C; Joshi MD; Guha M; Alam M; Kharbanda S; Kufe D
Prostate; 2012 Nov; 72(15):1659-68. PubMed ID: 22473899
[TBL] [Abstract][Full Text] [Related]
16. MUC1 oncoprotein is a druggable target in human prostate cancer cells.
Joshi MD; Ahmad R; Yin L; Raina D; Rajabi H; Bubley G; Kharbanda S; Kufe D
Mol Cancer Ther; 2009 Nov; 8(11):3056-65. PubMed ID: 19887552
[TBL] [Abstract][Full Text] [Related]
17. Survival of human multiple myeloma cells is dependent on MUC1 C-terminal transmembrane subunit oncoprotein function.
Yin L; Ahmad R; Kosugi M; Kufe T; Vasir B; Avigan D; Kharbanda S; Kufe D
Mol Pharmacol; 2010 Aug; 78(2):166-74. PubMed ID: 20444960
[TBL] [Abstract][Full Text] [Related]
18. Development of the Tumor-Specific Antigen-Derived Synthetic Peptides as Potential Candidates for Targeting Breast and Other Possible Human Carcinomas.
Okarvi SM; AlJammaz I
Molecules; 2019 Aug; 24(17):. PubMed ID: 31470531
[TBL] [Abstract][Full Text] [Related]
19. Intracellular MUC1 peptides inhibit cancer progression.
Bitler BG; Menzl I; Huerta CL; Sands B; Knowlton W; Chang A; Schroeder JA
Clin Cancer Res; 2009 Jan; 15(1):100-9. PubMed ID: 19118037
[TBL] [Abstract][Full Text] [Related]
20. Combination therapy of RY10-4 with the γ-secretase inhibitor DAPT shows promise in treating HER2-amplified breast cancer.
Su F; Zhu S; Ruan J; Muftuoglu Y; Zhang L; Yuan Q
Oncotarget; 2016 Jan; 7(4):4142-54. PubMed ID: 26716652
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
